Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bicycle Therapeutics Plc ADR (NQ: BCYC )

15.31 +0.17 (+1.16%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bicycle Therapeutics Plc ADR

< Previous 1 2 3 4 5 6 7 Next >
Bicycle Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From Bicycle Therapeutics
Via Business Wire
Expert Ratings for Bicycle Therapeutics
Via Benzinga
Bicycle Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Non-Voting Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics's Return On Capital Employed Insights
Via Benzinga
Bicycle Therapeutics PLC (NASDAQ: BCYC) Making Surprising Moves in Friday Session
Via Investor Brand Network
Why Bicycle Therapeutics Stock Raced Ahead Today
The company's latest attempt at capital raising seems to be having enviable success. 
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Stratasys, MillerKnoll, Nikola And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Nasdaq Composite gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session. Nikola Corporation (NASDAQ: NKLA) gained 18% to... 
Via Benzinga
Bicycle Therapeutics Announces Pricing of $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares
From Bicycle Therapeutics plc
Via Business Wire
14 Analysts Have This to Say About Bicycle Therapeutics
Via Benzinga
Recap: Bicycle Therapeutics Q1 Earnings
Via Benzinga
Analyst Ratings for Bicycle Therapeutics
Via Benzinga
Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Appoints Alethia Young as Chief Financial Officer
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in the TD Cowen Radiopharmaceutical Innovation Summit
From Bicycle Therapeutics plc
Via Business Wire
What 8 Analyst Ratings Have To Say About Bicycle Therapeutics
Via Benzinga
Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics and Orano Med Present Preclinical Bicycle® Radio-Conjugate Data at TIDES 2023
From Bicycle Therapeutics plc
Via Business Wire
Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology
From Bayer
Via Business Wire
Bicycle Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Collaboration With the German Cancer Research Center, to Discover and Develop Wholly Owned Bicycle® Radio Conjugates for a Range of Oncology Targets
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Enhances Leadership Team with Key Appointments
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
From Bicycle Therapeutics
Via Business Wire
Bicycle Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Phase I Dose Escalation Results from Ongoing Phase I/II Study of BT8009
From Bicycle Therapeutics
Via Business Wire
Bicycle Therapeutics to Participate in the SVB Securities Global Biopharma Conference
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium
From Bicycle Therapeutics plc
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.